← Fady I. Malik

Papers by Fady I. Malik

Page 1 · newest first

1. Safety and Efficacy of Omecamtiv Mecarbil by QRS Duration and Cardiac Resynchronization Therapy in GALACTIC-HFJACC Heart Failure · 2026
2. Left Ventricular Ejection Fraction Reductions During Long-Term Aficamten Treatment in Obstructive Hypertrophic Cardiomyopathy: Findings From FOREST-HCMJournal of Cardiac Failure · 2026
3. The Discovery of Ulacamten, a Cardiac Myosin Inhibitor for the Treatment of Heart Failure with Preserved Ejection FractionACS Medicinal Chemistry Letters · 2026
4. Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic CardiomyopathyCirculation · 2026
5. Aficamten for Symptomatic Nonobstructive Hypertrophic CardiomyopathyNew England Journal of Medicine · 2026
6. Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCMCirculation · 2026
7. The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyJournal of Cardiac Failure · 2026
8. Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (Redwood-HCM Cohort 4)Journal of the American College of Cardiology · 2023
9. Improving Heart Failure Therapeutics Development in the United StatesJournal of the American College of Cardiology · 2018
10. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
11. Aficamten in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
12. 26-a-11653-Acc Aficamten Versus Metoprolol in Patients With Hypertension and Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2026
13. 26-a-16519-Acc Electrocardiographic Changes and Associations With Echocardiographic Changes in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the Sequoia-HCM TrialJournal of the American College of Cardiology · 2026
14. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyEuropean Heart Journal · 2025
15. Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trialEuropean Journal of Heart Failure · 2026
16. The Use of Durable Medical Equipment in COURAGE ‐ ALS , a Phase 3, Multicentre, Randomized Clinical Trial for ALSMuscle & Nerve · 2026
17. Mitral Regurgitation in patients with HF and reduced ejection fraction: Insights from GALACTIC-HFEuropean Journal of Heart Failure · 2026
18. Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection FractionJACC Heart Failure · 2026
19. Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFEuropean Journal of Heart Failure · 2026
20. Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCMCirculation Heart Failure · 2025
21. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMCirculation Heart Failure · 2025
22. Abstract Or301: Preclinical characterization of CK-4021586, a new class of cardiac myosin inhibitors, for the treatment of heart failure with preserved ejection fractionCirculation Research · 2025
23. Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCMJournal of Cardiac Failure · 2025
24. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialCirculation · 2025
25. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyNew England Journal of Medicine · 2025
26. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trialEuropean Heart Journal · 2025
27. Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
28. Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trialAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2025
29. Aficamten Treatment for Symptomatic Obstructive Hypertrophic CardiomyopathyJACC Heart Failure · 2025
30. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialEuropean Heart Journal · 2025
31. Derisking Phase II Clinical Trials in Heart FailureJACC Basic to Translational Science · 2025
32. Reldesemtiv in Amyotrophic Lateral SclerosisJAMA Neurology · 2025
33. A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac MyosinInternational Journal of Toxicology · 2025
34. Aficamten vs Metoprolol for Obstructive Hypertrophic CardiomyopathyJACC Heart Failure · 2025
35. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCMJournal of the American College of Cardiology · 2024
36. Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysisEuropean Heart Journal · 2024
37. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
38. Aficamten and Cardiopulmonary Exercise Test PerformanceJAMA Cardiology · 2024
39. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
40. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trialEuropean Heart Journal · 2024
41. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
42. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
43. Super-relaxed myosins contribute to respiratory muscle hibernation in mechanically ventilated patientsScience Translational Medicine · 2024
44. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCMJournal of the American Heart Association · 2024
45. Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathyNature Cardiovascular Research · 2024
46. Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCMEuropean Journal of Heart Failure · 2024
47. Cardiac myosin inhibitor, CK-586, minimally reduces systolic function and ameliorates obstruction in feline hypertrophic cardiomyopathyScientific Reports · 2024
48. Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyNew England Journal of Medicine · 2024
49. Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac ContractilityJournal of Medicinal Chemistry · 2024
50. Pathogenic TNNI1 variants disrupt sarcomere contractility resulting in hypo- and hypercontractile muscle diseaseScience Translational Medicine · 2024